Limits...
Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T - PLoS ONE (2013)

Bottom Line: According to both Hans' and Choi's algorithms, the non-GCB type was predominant.Nevertheless, prognosis was good.In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study, we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans' algorithm and 11 (28%) were of the GCB-type according to Choi's algorithm. According to both Hans' and Choi's algorithms, the non-GCB type was predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB subgroups (Hans' algorithm: p = 0.57, Choi's algorithm: p = 0.99). Furthermore, the prognosis of localized nasal/paranasal DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

Show MeSH

Related in: MedlinePlus

Histological and immunohistochemical features.Diffuse infiltration and proliferation of large lymphoma cells (Hematoxylin–eosin staining).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585191&req=5

pone-0057677-g001: Histological and immunohistochemical features.Diffuse infiltration and proliferation of large lymphoma cells (Hematoxylin–eosin staining).

Mentions: Table 1 and Table 2 summarize the characteristics of the localized nasal/paranasal DLBCL patients. The median age of the 39 patients was 76 years (range, 33–98 years). The patient population comprised 21 men and 18 women. According to Choi’s algorithm, 11 of the 39 patients (28%) were of the GCB- type and 28 (72%) were of the non-GCB- type. According to Hans’ algorithm, 11 (28%) were of the GCB- type and 28 of the 39 patients (72%) were of the non-GCB type (Table 3). According to the Ann Arbor classification, 33 patients were at clinical stage IE and 6 were at stage IIE. According to the International Prognostic Index, 4 patients were at low- intermediate risk and 13 were at low risk. Histologically, all cases were classified as DLBCL (Fig. 1). All patients were newly presenting with no prior treatment history.


Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T - PLoS ONE (2013)

Histological and immunohistochemical features.Diffuse infiltration and proliferation of large lymphoma cells (Hematoxylin–eosin staining).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585191&req=5

pone-0057677-g001: Histological and immunohistochemical features.Diffuse infiltration and proliferation of large lymphoma cells (Hematoxylin–eosin staining).
Mentions: Table 1 and Table 2 summarize the characteristics of the localized nasal/paranasal DLBCL patients. The median age of the 39 patients was 76 years (range, 33–98 years). The patient population comprised 21 men and 18 women. According to Choi’s algorithm, 11 of the 39 patients (28%) were of the GCB- type and 28 (72%) were of the non-GCB- type. According to Hans’ algorithm, 11 (28%) were of the GCB- type and 28 of the 39 patients (72%) were of the non-GCB type (Table 3). According to the Ann Arbor classification, 33 patients were at clinical stage IE and 6 were at stage IIE. According to the International Prognostic Index, 4 patients were at low- intermediate risk and 13 were at low risk. Histologically, all cases were classified as DLBCL (Fig. 1). All patients were newly presenting with no prior treatment history.

Bottom Line: According to both Hans' and Choi's algorithms, the non-GCB type was predominant.Nevertheless, prognosis was good.In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study, we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans' algorithm and 11 (28%) were of the GCB-type according to Choi's algorithm. According to both Hans' and Choi's algorithms, the non-GCB type was predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB subgroups (Hans' algorithm: p = 0.57, Choi's algorithm: p = 0.99). Furthermore, the prognosis of localized nasal/paranasal DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

Show MeSH
Related in: MedlinePlus